The Battle For OGS
Executive Summary
Celltech's hostile bid for OGS may have scuppered the company's cosy merger plans with CAT. But OGS isn't giving in without a fight. And Celltech's offer may even prove beneficial to OGS shareholders, bumping up the firm's price-tag for CAT--or another suitor.
You may also be interested in...
Glycoform Ltd.
Glycoform Ltd. aims to leverage the pioneering glyco-chemistry research of its Oxford University founders to develop targeted drug delivery systems and to improve the safety and efficacy of protein therapeutics, including monoclonal antibodies, by taking advantage of the way specific oligosaccharides, or sugar motifs, can affect the properties of the proteins they decorate.
CAT Fight with Abbott: The Calculus of Royalty Offsets and Partnering Reputation
The fight between Abbott Laboratories and Cambridge Antibody Technology over two partly overlapping royalty-giveback clauses in their contract on Humira has implications far beyond the money--which itself is not inconsiderable. Abbott could theoretically save itself some $60 million in royalty fees, but it could also win itself a name for playing hardball with its partners, even in the event of a major drug development success.
Biotechs Beware: Royalty Offset Clauses Can Seriously Damage Your Health
Cambridge Antibody's royalty dispute with partner Abbott over potential blockbuster Humira sends a sobering message to biotechs: beware poorly-constructed royalty offset clauses. The argument won't help Abbott's partnering image, either.